Telisotuzumab Vedotin (ABBV-399)
CAS: 1714088-51-3
Description:
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADC) targeting the c-Met protein, which is overexpressed in many solid tumors. The drug combines an anti-c-Met monoclonal antibody with the cytotoxic agent monomethyl auristatin E (MMAE), which disrupts microtubules and kills cancer cells. It delivers MMAE directly to c-Met-expressing tumor cells, making it an effective treatment for non-small cell lung cancer (NSCLC) and other solid tumors.
Key Features:
- c-Met Targeting: The antibody binds specifically to c-Met, which is overexpressed in many cancer cells, enabling precise drug delivery.
- Cytotoxic Agent (MMAE): MMAE inhibits microtubule function, leading to cancer cell death.
- Linker Technology: A stable and cleavable mc-val-cit-PABC linker ensures MMAE reaches the tumor cells, enhancing targeted delivery.
Applications:
- Cancer Treatment: Targets and destroys c-Met-positive cancer cells, especially in NSCLC.
- Targeted Therapy: Delivers MMAE directly to cancer cells, reducing side effects and sparing healthy tissue.
- Monoclonal Antibody Therapy: Provides a targeted treatment for patients with c-Met-expressing tumors, offering a more precise chemotherapy approach.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.